Abstract Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.
Introduction

Guideline objectives
Mortality and morbidity from colorectal cancer have substantially increased in Japan recently. According to the vital statistics for Japan in 2008, colorectal cancer accounted for the largest number of deaths from malignant neoplasms in women and the third largest number in men, after lung cancer and gastric cancer. Nevertheless, the number of deaths from colorectal cancer per unit population has increased approximately tenfold during the past 50 years. Many new treatment methods have been developed during that time, and their use in combination with advances in diagnostic methods has led to a steady improvement in the results of treatment. However, there are differences in treatment among medical institutions in Japan that provide medical care for patients with colorectal cancer, and these differences may lead to differences in the results of treatment.
Under such circumstances, the JSCCR guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010), which are intended for doctors (general practitioners and specialists) who provide medical care for patients with colorectal cancer at various disease stages and conditions, have been prepared for the following purposes: (1) to show standard treatment strategies for colorectal cancer; (2) to eliminate disparities among institutions in terms of treatment; (3) to eliminate unnecessary treatment and insufficient treatment; and (4) to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public [1] .
The following are expected to be achieved with these Guidelines: (1) improved treatment of colorectal cancer in Japan; (2) improved results of such treatment; (3) reduced human and financial burdens; and (4) increased benefits for patients.
How to use these Guidelines
These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan, so these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. However, these Guidelines provide only general recommendations for choosing treatment strategies for colorectal cancer, and they do not control or limit treatment strategies or treatment methods that are not described herein. These Guidelines can also be used as a document to explain the rationale for selecting treatment strategies and treatment methods that differ from those described in these Guidelines.
JSCCR is responsible for the statements in these Guidelines. However, the personnel directly in charge of treatment, not the JSCCR or the Guideline Committee, are responsible for the outcome of treatment.
Method used to prepare these Guidelines
(1) Classification of evidence Levels of evidence were classified as ''high-level evidence'' or ''low-level evidence'' as follows:
[High-level evidence]
• Meta-analyses of systematic reviews/randomized controlled trials (RCTs),
• randomized controlled trials, • nonrandomized controlled trials,
• cohort studies, case-control studies, and cross-sectional studies.
[Low-level evidence]
• Case series studies, case studies, expert opinions, and clinical experience.
(2) Clinical Questions and classification of recommendation categories
As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions (CQ), and recommendations were made. Each recommendation in response to a CQ is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. In determining the recommendation categories, in addition to an evaluation of the internal validity of the source of evidence for each recommendation, a comprehensive investigation of the internal validity, external validity, and clinical applicability of each recommendation was performed, considering the following points: (1) the treatment method has a clear scientific rationale and is the best treatment method conceivable; (2) the treatment method is as safe as possible, causes little invasion, and maintains physical function; (3) the treatment method is cost-effective and imposes the smallest financial burden on the patient; and (4) the treatment method is in line with the treatment methods used in actual clinical practice settings in Japan.
Recommendations with which all members of the Guideline Committee agreed were classified as category A or category B recommendations. Recommendations with which three or more members of the Committee disagreed were classified as category D recommendations, and all other recommendations were classified as category C recommendations. The category D recommendations are not included in these Guidelines.
Classification of recommendation categories:
• Category A: unanimous recommendations by the Guideline Committee based on high-level evidence • Category B: unanimous recommendations by the Guideline Committee based on low-level evidence • Category C: recommendations that were not agreed to completely by the members of the Guideline Committee, irrespective of the level of evidence • Category D: recommendations that were not agreed to by three or more members of the Guideline Committee
Literature search
Initially, the literature search was performed for the following 12 broad categories. Then, a further search was done as needed with additional search techniques. The PubMed and Ichushi-Web databases were selected for the search, and the English and Japanese literature was searched in both databases for the period from January 1983 to December 2007. The task of searching was shared by four members of the medical library; the four members created a search formula by discussion with the Committee members in charge of each item and collected literature during the search period (January 2008 to July 2008). For categories (7) and (8) , however, April 2010 was set as the end of the search period. In addition, secondary documents such as UpToDate and literature collected by manual searching were added and critically examined as needed, and other documents such as minutes and guidelines were included as necessary. Of the 8,043 references identified as a result of the searches (5,305 in the PubMed database and 2,738 in the Ichushi-Web database), 1,618 references were retrieved and examined critically (Table 1) .
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Treatment guidelines for colorectal cancer
Chapter 1: Treatment strategies for stage 0 to stage III colorectal cancer
Endoscopic treatment
General principles underlying the indications for endoscopic resection (Fig. 1 ) • There is little possibility of lymph node metastasis, and the size and location of the tumor make en bloc resection possible.
Indication criteria for endoscopic resection:
(1) Intramucosal carcinoma or carcinoma with slight submucosal invasion (2) Maximum diameter \2 cm (3) Any macroscopic type
• Endoscopic treatment is a method of endoscopically resecting lesions in the large bowel and of collecting the resected specimens.
• Endoscopic treatment methods consist of polypectomy, 1 endoscopic mucosal resection (EMR), 2 and endoscopic submucosal dissection (ESD). 3 • In determining the indication for endoscopic treatment and the treatment method, information on the size, predicted depth of invasion, and morphology of the tumor is essential, and the histological type of the tumor should also be taken into consideration.
Comments
• Endoscopic resection is intended for both diagnosis and treatment. It consists of total excisional biopsy in which curability and the need for additional intestinal resection are assessed by histopathological examination of the resected specimens (CQ-1).
• En bloc resection is desirable for accurate diagnosis of the status of carcinoma invasion in the resection margin and the deepest area. • 2 cm is the largest size of a tumor that can be easily resected en bloc by polypectomy or snare EMR [3] (CQ-2).
• Colorectal ESD has not become a common treatment method, because the technique is difficult and there is a high risk of complications (perforation) [3] .
• EMRC (EMR using a cap) involves a high risk of perforation when used for colon lesions.
• If the preoperative diagnosis is intramucosal carcinoma, piecemeal resection can be performed. It should be noted, however, that piecemeal resection is associated with a high incomplete resection rate and a high local recurrence rate [3] .
2. Surgical treatment (Fig. 2) • The extent of lymph node dissection to be performed during colorectal cancer surgery is determined based on the preoperative clinical findings (c) or on the extent of 1 In polypectomy, a snare is placed on the stalk of the lesion, and the lesion is electrocauterized using a high-frequency current. This method is mainly used for protruding lesions. 2 In EMR, the lesion is elevated through the local injection of a liquid such as physiological saline into the submucosa, and the lesion is electrocauterized just as in polypectomy. This method comprises the snare method [2] and EMR using a cap (EMRC). It is mainly used for superficial tumors and large sessile lesions. 3 In ESD, the lesion is elevated through the local injection of a liquid such as sodium hyaluronate solution into the submucosa of the perilesional area; then, circumferential incision of the mucosa surrounding the lesion and dissection of the submucosa are performed with a special knife [3] . ESD is mainly indicated for large tumors that cannot be resected by EMR. lymph node metastasis and depth of wall invasion by the tumor observed intraoperatively (s).
• If lymph node metastasis is suspected based on the preoperative/intraoperative diagnostic findings, D3 dissection is performed.
• If no lymph node metastases are observed based on the preoperative/intraoperative diagnostic findings, lymph node dissection is performed based on the depth of wall invasion by the tumor [4] .
(1) Lymph node dissection is unnecessary for M cancer (D0), because M cancer is not accompanied by lymph node metastasis; however, D1 dissection can be performed because the accuracy of the preoperative diagnosis of invasion depth may be insufficient. (2) D2 dissection is necessary for SM cancer, because the incidence of lymph node metastasis is approximately 10% and because SM cancer is often accompanied by intermediate lymph node metastasis. (3) Although there is insufficient evidence describing the area of dissection for MP cancer, at the very least D2 dissection is necessary. However, D3 dissection can be performed, because MP cancer is often accompanied by main lymph node metastases and because preoperative diagnosis of depth of invasion is not very accurate.
Surgical treatment of rectal cancer:
• The principle for proctectomy is TME (total mesorectal excision) or TSME (tumor-specific mesorectal excision) [5] [6] [7] [8] .
[Indications criteria for lateral lymph node dissection]
• Lateral lymph node dissection is indicated when the lower border of the tumor is located distal to the peritoneal reflection and has invaded beyond the muscularis propria [9] .
[Local rectal resection]
• Local resection is indicated for cM cancer and cSM cancer (slight invasion) located distal to the second Houston valve (peritoneal reflection). Approaches for local resection are classified into transanal resection, transsphincter resection, and parasacral resection [10] . Transanal resection includes the conventional method in which the tumor is resected under direct vision and transanal endoscopic microsurgery (TEM) [11] . More proximal lesions can be resected by TEM than by the conventional method.
[Autonomic nerve-preserving surgery]
• The autonomic nervous system relating to surgery of rectal cancer consists of the lumbar splanchnic nerves, superior hypogastric plexus, hypogastric nerves, pelvic splanchnic nerves, and the pelvic plexus. Considering factors such as the degree of cancer progression and the presence or absence of macroscopic nerve invasion, preservation of autonomic nerves is attempted in order to preserve urinary and sexual functions as much as possible, provided that curability is unaffected.
Laparoscopic surgery:
• • An analysis of 2916 cases of rectal cancer in the project study by the JSCCR showed that the lateral lymph node metastasis rate in patients whose lower tumor border was located distal to the peritoneal reflection and whose cancer had penetrated through the rectal wall was 20.1% (only patients who underwent lateral lymph node dissection) ( Table 2 ). After performing lateral lymph node dissection for the indication mentioned above, the risk of intrapelvic recurrence decreased by 50%, and the 5-year survival rate improved by 8-9% [9] .
• The lateral lymph node metastasis rate of patients whose lower tumor border was located distal to the peritoneal reflection and who had lymph node metastasis in the mesorectum was 27%.
• Urinary function and male sexual function may be impaired after lateral lymph node dissection, even if the autonomic nervous system is completely preserved.
[Aggregate data from the Colorectal Cancer Registry]
• The incidence of lymph node metastasis according to site and depth of invasion, curative resection rate, and 5-year survival rate is shown in Tables 3, 4 , and 5 [4] .
• The 5-year survival rates after curative resection of stage 0 to stage III colorectal cancer according to site were: all sites 81.3%; colon 83.7%, rectosigmoid 81.2%; Ra-Rb rectum 77.1%.
Chapter 2: Treatment strategies for stage IV colorectal cancer ( Fig. 3) • Stage IV colorectal cancer is associated with synchronous distant metastasis to any of the following organs: liver, lung, peritoneum, brain, distant lymph nodes, or other organs (e.g., bone, adrenal gland, spleen).
• If both the distant metastases and the primary tumor are resectable, curative resection of the primary tumor is performed, and resection of the distant metastases is considered.
• If the distant metastases are resectable but the primary tumor is unresectable, in principle, resection of the primary tumor and distant metastases is not performed, and another treatment method is selected.
• If the distant metastases are unresectable but the primary tumor is resectable, the indication for the resection of the primary tumor is determined, based on the clinical symptoms of the primary tumor and the impact on the prognosis (CQ-4). 
• The incidence of synchronous distant metastasis is shown in Table 6 .
• Distant metastasis associated with peritoneal dissemination (CQ-5).
(1) Complete resection is desirable for P1.
(2) Complete resection is considered for P2 when easily resectable. (3) The efficacy of resection of P3 has not been demonstrated.
Chapter 3: Treatment strategies for recurrent colorectal cancer (Fig. 4) • The goal of treatment for recurrent colorectal cancer is to improve the prognosis and the patient's QOL.
• Treatment methods include surgery, systemic chemotherapy, arterial infusion chemotherapy, thermal coagulation therapy, and radiotherapy.
• An appropriate treatment method is selected with the informed consent of the patient in view of a variety of factors, such as the prognosis, complications, and QOL expected after treatment. No. of patients Extent of lymph node metastasis detected histologically
All sites (C-P) Curative resection rate = number of patients with histological curability A cancer/total number of patients who underwent surgery
Staging was performed according to the rules set forth in the Japanese Classification of Colorectal Carcinoma (6th edition) • If recurrence is observed in a single organ and complete surgical resection of the recurrent tumor(s) is possible, resection is strongly considered.
• If recurrence is observed in more than a single organ, resection can be considered if the recurrent tumors in all of the organs are resectable [12, 13] ; however, there is no consensus on the effects of treatment.
• Some authors believe that resection of liver or lung metastases should be performed only after a certain observation period to rule out occult metastases [14] .
• Treatment methods for hematogenous metastases (see ''Chapter 4: Treatment strategies for hematogenous metastases'').
• Local recurrences of rectal cancer take the form of anastomotic recurrences and intrapelvic recurrences.
(1) Resection is considered for resectable recurrences, (2) radiotherapy and systemic chemotherapy, either alone or in combination, are considered for unresectable recurrences.
Comments [Local recurrence of rectal cancer]
• The extent of spread of the recurrent tumor is evaluated by diagnostic imaging, and resection is considered only for patients in whom complete resection can be expected, after taking into consideration such factors as the pattern of recurrence, symptoms, and physical findings (CQ-6). Chapter 4: Treatment strategies for hematogenous metastases (Fig. 5) 
Treatment strategies for liver metastases
• Treatment of liver metastases is broadly divided into hepatectomy, systemic chemotherapy, hepatic arterial infusion therapy, and thermal coagulation therapy.
• Hepatectomy is recommended for liver metastases when curative resection is possible.
• Hepatectomy consists of systematic resection and partial (nonsystematic) resection.
Indication criteria for hepatectomy (1) the patient is capable of tolerating surgery, (2) the primary tumor has been controlled or can be controlled, (3) the metastatic liver tumor can be completely resected, (4) there are no extrahepatic metastases or they can be controlled, (5) the function of the remaining liver will be adequate.
• Systemic chemotherapy and hepatic arterial infusion therapy, either alone or in combination, are considered for patients with unresectable liver metastases whose general condition can be maintained at a certain level or higher (PS 0 to PS 2).
• Thermal coagulation therapy consists of microwave coagulation therapy (MCT) and radiofrequency ablation (RFA).
• If the patient's general condition is poor (PS C 3), best supportive care (BSC) is provided.
Comments [Hepatectomy]
• There are reports showing the efficacy of hepatectomy in patients who have controllable extrahepatic metastases (mainly lung metastases) in addition to liver metastases [12, 13, 15, 16] (CQ-7).
• The efficacy of systemic chemotherapy and hepatic arterial infusion therapy after hepatectomy has not been established (CQ-8).
• The safety of preoperative chemotherapy for resectable liver metastases has not been established (CQ-9).
[Treatment methods other than resection]
• Systemic chemotherapy or hepatic arterial infusion therapy with anticancer drugs is performed alone or in combination for patients with unresectable liver metastases (CQ-10).
Treatment strategies for lung metastases
• Treatment of lung metastases consists of pulmonary resection and chemotherapy.
• Pulmonary resection is considered if the metastatic lung tumor is resectable.
• Pulmonary resection consists of systematic resection and partial (nonsystematic) resection.
Indication criteria for pulmonary resection (1) The patient is capable of tolerating surgery, (2) the primary tumor has been controlled or can be controlled, (3) the metastatic lung tumor can be completely resected, (4) there are no extrapulmonary metastases, or they can be controlled, (5) the function of the remaining lung will be adequate.
• Systemic chemotherapy is considered for patients with unresectable lung metastases whose general condition can be maintained at a certain level or higher.
• Even if the patient cannot tolerate surgery, stereotactic radiotherapy is considered if the primary tumor and extrapulmonary metastases are controlled or can be controlled and the number of lung metastases is no more than three or four.
• If the patient's general condition is poor, appropriate BSC is provided.
Treatment strategies for brain metastases
• Brain metastases are often detected as a part of a systemic disease, and surgical therapy or radiotherapy is considered for lesions in which treatment can be expected to be effective.
• The optimal treatment method is selected after considering the patient's general condition and the status of other metastatic tumors, and evaluating the sizes and locations of metastatic tumors and the number of lesions.
• Radiotherapy is considered for patients with unresectable metastases.
[Surgical therapy] Indications criteria for removal of brain metastases [17] (1) The patient has a life expectancy of at least several months, (2) resection will not cause significant neurologic symptoms, (3) there are no metastases to other organs, or they can be controlled.
[Radiotherapy]
• The purpose of radiotherapy is to relieve symptoms, such as cranial nerve symptoms and intracranial hypertension symptoms, and to prolong survival time by reducing locoregional relapse.
• Whole-brain radiotherapy is considered for patients with multiple brain metastases and for patients with a solitary brain metastasis for which surgical resection is not indicated.
• Stereotactic irradiation is considered when the number of brain metastases is no more than three or four and the maximum diameter of each metastasis does not exceed 3 cm.
Treatment strategies for hematogenous metastases to other organs
• Resection is also considered for other hematogenous metastases, such as to the adrenal glands, skin, and spleen, if they are resectable. However, patients with such metastases often have metastasis to more than one organ, and chemotherapy or radiotherapy is often indicated.
Chapter 5: Chemotherapy
• Chemotherapy consists of adjuvant chemotherapy to prevent postoperative recurrence and systemic chemotherapy to treat unresectable colorectal cancer.
• Commonly used anticancer drugs that have been approved for the indication of colorectal cancer and are covered by Japanese National Health Insurance are:
Oral drugs 5-FU, tegafur, UFT, doxifluridine (5 0 -DFUR), carmofur (HCFU), S-1, UFT ? leucovorin (LV), capecitabine, etc. Injection drugs 5-FU, mitomycin C, irinotecan (CPT-11), 5-FU ? l-leucovorin (l-LV), oxaliplatin (L-OHP), bevacizumab, cetuximab, panitumumab, etc.
Adjuvant chemotherapy
• Postoperative adjuvant chemotherapy is systemic chemotherapy that is performed after surgery to prevent recurrence and improve the prognosis of patients who have undergone R0 resection [18] .
General principles underlying the indications for systemic chemotherapy 
the patient has recovered from postoperative complications, if any (5) the patient has provided written informed consent, (6) the patient has no serious complications (in particular:
no intestinal obstruction, diarrhea, or fever).
• For patients who have stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [19, 20] (CQ-12).
Recommended therapies (listed in the order of the date of their coverage by Japanese National Health Insurance)
Recommended administration period (CQ13)
• In principle, the administration period is 6 months. 2. Chemotherapy for unresectable colorectal cancer (Fig. 6) • In the absence of chemotherapy, the median survival time (MST) of patients with unresectable colorectal cancer has been reported to be approximately 8 months.
Although their MST has been extended to approximately 2 years as a result of recent chemotherapy, unresectable colorectal cancer is still difficult to cure.
• The purpose of chemotherapy is to prolong survival time and control symptoms by delaying tumor enlargement.
• Phase III clinical trials in PS 0 to PS 2 patients have shown significantly longer survival time in the chemotherapy groups than in the best supportive care (BSC) groups that did not receive anticancer drugs [27] [28] [29] .
• Unresectable colorectal cancer may become resectable after successful chemotherapy.
General principles underlying the indications for systemic chemotherapy (1 CPT-11
<KRAS wild-type> CPT-11+ cetuximab or cetuximab/panitumumab monotherapy (a) For patients whose cancer has become resistant to a regimen that includes L-OHP:
FOLFIRI (or CPT-11 alone) ± cetuximab/panitumumab [46, 47] .
(b) For patients whose cancer has become resistant to a regimen that includes CPT-11:
(1) FOLFOX [34, 48] ± bevacizumab [49] , CapeOX 2 [50] ± bevacizumab, (2) CPT-11 ? cetuximab [51] .
(c) For patients whose cancer has become resistant to a regimen that includes 5-FU, L-OHP, and CPT-11:
Cetuximab/panitumumab monotherapy [52] [53] [54] [55] .
Comments
• Careful attention must be paid when using CPT-11 to treat patients with constitutional jaundice, such as caused by Gilbert's syndrome, or to treat patients with high serum bilirubin values. Relationships between genetic polymorphisms of enzymes that metabolize CPT-11 and toxicity have been suggested (see ''Side Memo 2'').
Chapter 6: Radiotherapy
• Radiotherapy is used to treat patients with locally advanced rectal cancer, either as an adjuvant therapy after surgery to prevent recurrence, or before surgery to reduce tumor volume and preserve the anal sphincter, and also as palliative care to relieve the symptoms and prolong the survival times of patients with unresectable colorectal cancer who have symptomatic lesions.
Adjuvant radiotherapy
• Adjuvant radiotherapy is classified into three categories, according to the timing of surgery and radiation therapy: preoperative radiotherapy, intraoperative radiotherapy, and postoperative radiotherapy.
• The purpose of adjuvant radiotherapy is to improve the local control rate and the survival rate of rectal cancer patients. In addition the purpose of preoperative radiotherapy is to improve the anal sphincter preservation rate and resection rate.
• Preoperative radiotherapy is indicated for patients with T stage clinically diagnosed as ''invasion depth cSS/cA or deeper or cN-positive;'' postoperative radiotherapy is indicated for patients with T stage pathologically diagnosed after surgery as ''invasion depth pSS/pA or deeper or pN-positive;'' and intraoperative radiotherapy is indicated for surgical dissection plane positive (RM?) cancer or cancer with invasion close to the dissection plane (RM±).
• Radiotherapy is delivered with a linear accelerator, with electron beams being used for intraoperative radiotherapy and photon beams for external radiotherapy.
Comments
• Preoperative radiotherapy (CQ-17).
1. Preoperative radiotherapy has the following advantages: seeding during surgery can be prevented by inactivating lesions with irradiation; a high percentage of tumor cells are normo-oxic and radiosensitive, because blood flow to the tumor is maintained; the small bowel is not fixed within the pelvic cavity, thereby resulting in low radiation-induced delayed toxicity, which means less toxic than postoperative setting; improvements in the resection rate and anal sphincter preservation can be expected because of tumor size reduction [56] . 2. Preoperative radiotherapy has the following disadvantages: early-stage patients may be subjected to overtreatment and postoperative complications may increase. 3. Twelve phase III clinical trials of preoperative radiotherapy (without chemotherapy) have been reported [56] , and in 5 of the 12 trials the local control rate in the group that received preoperative radiotherapy was significantly higher than that in the surgery-alone group. However, an improvement in the survival rate was observed in only 1 trial [57] . 4. Two meta-analyses of radiotherapy showed improvement in the local control rate and improvement in the survival rate in the groups that received doses of 30 Gy or more. However, there is controversy as to whether there is improvement in the survival rate [58, 59] . 5. Trials of short-course radiotherapy with 5 Gy per fraction have been conducted, mainly in Europe [57, 60] . Because the late effects of radiation depend on the fraction size, long-term follow-up for late adverse effects, such as anal dysfunction and bowel dysfunction, is necessary. 6. In the Dutch CKVO 95-04 trial, which compared preoperative radiotherapy (25 Gy delivered in five fractions in 1 week) ? TME with TME alone to investigate the significance of adding short-course radiotherapy to TME, the 5-year local control rate was significantly higher in the combination therapy group but there was no significant difference between the two groups in the 5-year survival rate [60, 61] . The incidences of sexual dysfunction and bowel dysfunction were higher in the preoperative radiation combination therapy group than in the surgery-alone group [62, 63] . 7. The effect of preoperative radiotherapy in reducing the size of the primary tumor may enable sphincter preservation. When the purpose of the preoperative radiotherapy is sphincter preservation, it is recommended to perform surgery after allowing an appropriate period for the tumor to decrease in size (6-8 weeks after the completion of radiotherapy) [64] . 8. In Europe, three phase III clinical trials, including the EORTC trial, were performed to investigate the usefulness of adding chemotherapy to preoperative radiotherapy. The incidence of acute-phase adverse events was significantly higher in the preoperative chemoradiotherapy groups, but the pathologic complete response rates (pCR) were significantly higher than in the preoperative radiotherapy alone groups. In two trials (the exception being the short-course radiotherapy trial), the local recurrence rate was significantly lower in the preoperative chemoradiotherapy group, and there was no significant difference between the two groups in terms of sphincter preservation or survival rate [65] [66] [67] . 9. In a phase III clinical trial that compared preoperative chemoradiotherapy and postoperative chemoradiotherapy, there was no significant difference in the 5-year survival rate, but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group. Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [68] .
Palliative radiotherapy a. Intrapelvic lesions (CQ-18)
• The purpose of palliative radiotherapy for intrapelvic lesions is to relieve symptoms such as pain, hemorrhage, and bowel movement disorders caused by intrapelvic tumors.
• The target volume includes the tumor that is causing the symptoms.
[Dose and fractionation]
• A total dose of 45-50 Gy is administered in 1.8-2.0 Gy per fraction.
• Depending on the patient's general condition, such as performance status, and the severity of the symptoms, radiotherapy may be completed in a shorter term with a larger fraction size, for example 30 Gy in 10 fractions over 2 weeks.
b. Extrapelvic lesions (1) Bone metastases
• The purpose of palliative radiotherapy for bone metastases is to achieve pain relief, prevent pathological fractures, and prevent and treat spinal cord paralysis.
• The target volume includes the metastatic bone lesions causing the symptoms.
• Local field radiotherapy, such as 30 Gy in 10 fractions and 20 Gy in 5 fractions, is widely performed. • When whole brain radiotherapy is performed, 30 Gy in 10 fractions is the standard treatment. If long-term survival is expected, prolonged fractionated radiotherapy, such as 37.5 Gy in 15 fractions and 40 Gy in 20 fractions, is considered.
• When stereotactic radiosurgery is performed, a peripheral dose of [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Gy is delivered in a single fraction.
Chapter 7: Palliative care
• Palliative care is a general term for palliative treatment of various mental and physical symptoms related to cancer.
• Palliative care extends from the time the diagnosis of cancer is made to the end stage, and the care provided should depend on the disease stage and symptoms.
• In principle, cancer treatment should be performed under conditions in which symptom relief is achieved [69] , and palliative care should be started at the same time as surgical treatment and chemotherapy.
• Palliative care to improve the QOL of patients with end-stage colorectal cancer includes:
(1) pain relief, (2) surgical treatment, (3) chemotherapy, (4) radiotherapy, (5) counseling for psychiatric symptoms.
Chapter 8: Surveillance after surgery for colorectal cancer
Surveillance for recurrence after curability A resection of colorectal cancer
• Surveillance is not required for stage 0 (pM cancer) if the resection margin is cancer-free. However, when evaluation of the resection margin is difficult, colonoscopy is performed 6 months to 1 year later to determine whether local recurrence is present.
• In principle, the duration of surveillance is 5 years after surgery, but the surveillance examinations are scheduled at shorter intervals during the first 3 years after surgery.
• It should be noted that there is a high incidence of lung metastasis and local recurrence after surgery for rectal cancer.
• As a general rule, the duration of surveillance for anastomotic recurrence is until 3 years after surgery.
• The following is an example of a surveillance schedule after curative resection of stage I to stage III colorectal cancer that was designed on the basis of the results of a retrospective investigation of factors such as the common sites and the incidence of recurrence and the efficacy of treatment (Fig. 7) .
Surveillance after curability B resection of colorectal cancer and after resection of recurrent tumors
• The same surveillance method as for stage III colorectal cancer is used. It should be noted that recurrence and re-recurrence are common in organs that were previously operated on.
Surveillance of metachronous multiple cancer
• Colonoscopy is performed for surveillance of metachronous multicentric colorectal cancer.
Comments [Aim of surveillance]
• [Recurrence rate, sites of recurrence, times of recurrence]
• The results of a review of the project study by the JSCCR are shown in Figs. 8, 9 and Tables 7, 8 , 9, 10. The subjects were patients who underwent curative resection of colorectal cancer between 1991 and 1996 at the 14 institutions that participated in the project, and the follow-up period was 6-11 years.
(1) Times of the recurrences and sites of the recurrences ( Fig. 9 ; Tables 7, 9, 10).
• More than 80% of the recurrences were detected within 3 years after surgery, and more than 95% of the regcurrences were detected within 5 years after surgery.
• The overall incidence of recurrence more than 5 years after surgery was less than 1%.
• Among lung recurrences, 5% of recurrences were detected more than 5 years after surgery.
• More than 95% of the anastomotic recurrences were detected within 3 years after surgery.
• Local recurrence and lung recurrence were more frequent in rectal cancer than in colon cancer.
• There have been reports regarding recurrences after curative resection in Europe and the United States showing that approximately 50% of the recurrences were detected within 1 year after surgery, that approximately 70% of the recurrences were detected within 2 years after surgery [75, 76] ; and that in most patients the recurrences were detected within 5 years after surgery [76] .
(2) Characteristics according to stage ( Fig. 8 ; Tables 7, 8) 1. Stage I
• The recurrence rate of pSM cancer was approximately 1% in both colon cancer and rectal cancer.
• The overall recurrence rate of pMP cancer was 6.4%, and it was 5.0% in colon cancer and 8.3% in rectal cancer.
• Two-thirds of the recurrences were detected within 3 years after surgery, and the overall incidence of recurrence more than 5 years after surgery was less than 0.2% among all patients.
Stage II, Stage IIIa, and Stage IIIb
• The recurrence rate increased with the stage.
• 78-90% of recurrences were detected within 3 years after surgery, and the overall incidence of recurrence more than 5 years after surgery was less than 1% among all patients. 
Project study of the JSCCR: patients in years 1991-1996 Table 9 Recurrence rate according to the site of the first recurrence after curative resection of colorectal cancer and cumulative incidence of recurrence according to the number of years after surgery
Site of first recurrence
Recurrence rate (no. of patients with recurrence (including overlaps) [Surveillance of metachronous multiple primary cancer]
• A past medical history of colorectal cancer, regardless of stage, is a risk factor for metachronous colorectal cancer [77] .
• The recommended interval between colonoscopy ranged from 1 to 5 years, depending on the report [78] .
• There was no evidence indicating the necessity of periodic detailed examinations for cancer in other organs (multiple cancer) after surgery for colorectal cancer (CQ-19).
Clinical questions
CQ-1: Indication criteria for additional treatment after endoscopic resection (Fig. 10) Recommendation: Category B
• Surgical resection is preferable when the vertical margin is positive.
• If any of the following findings is observed during histological examination of the resected specimen, intestinal resection with lymph node dissection is considered as an additional treatment:
(1) Depth of SM invasion C1,000 lm, (2) vascular invasion positive, (3) poorly differentiated adenocarcinoma, signet-ring cell carcinoma, or mucinous carcinoma [79] , (4) Grade 2/3 budding at the site of deepest invasion [79] .
Note:
• ''Vertical margin-positive'' means that carcinoma is exposed at the submucosal margin of the resected specimen.
• Depth of SM invasion is measured by the method described in ''Side Memo 1'' (Fig. 11 ).
• Vascular invasion consists of lymphatic and venous invasion (Figs. 12, 13, 14 ).
• The method for assessing budding is described in Fig. 15 .
The principle for the treatment of pSM carcinomas, which are invasive carcinomas, is intestinal resection with lymph node dissection. However, some pSM carcinomas have a very low risk of metastasis, and the purpose of these Fig. 10 Treatment strategies for pSM cancer after endoscopic resection criteria is to minimize the need for additional resections that eventually result in overtreatment of such patients. While no diagnostic methods make it possible to predict lymph node metastasis (pN) without fail, the degree of risk of metastasis can be used as a basis for determining whether or not to perform additional treatment.
Factors such as the depth of submucosal invasion (SM invasion depth) [80] , histological type (such as poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous carcinoma [79] ), the presence of a poorly differentiated area and muconodules at the site of deepest invasion, budding, and vascular invasion have been reported to be risk factors for regional lymph node metastasis by pSM carcinoma [79, 81] .
The above criteria for determining whether additional treatment is indicated were prepared based on the following 3 criteria for performing additional intestinal resection of pSM carcinoma described in the Japanese Classification of Colorectal Carcinoma (2nd edition, 1980): (1) obvious intravascular carcinoma invasion; (2) poorly differentiated adenocarcinoma or undifferentiated carcinoma; (3) massive carcinoma invasion extending to the vicinity of the margin [82] . The description of ''massive carcinoma invasion'' in the 4th edition of the Japanese Classification of Colorectal Carcinoma was revised to the following more specific description in the 5th edition (1994): invasion deeper than ''very shallow invasion'' (e.g., invasion exceeding approximately 200 to 300 lm) [83] . Subsequent case series studies in Japan have shown that ''200-300 lm'' can be extended to 1,000 lm [84]. According to the results of the project study by the JSCCR, the lymph node metastasis rate of colorectal carcinoma with an SM invasion depth of 1,000 lm or more was 12.5% (Table 11 ) [80, 84] . However, approximately 90% of patients with a depth of invasion of 1,000 lm or more did not have lymph node metastasis, and it is important to determine whether additional treatment is indicated after sufficiently considering other factors in addition to depth of SM invasion, such as whether other risk factors for lymph node metastasis are present, the physical and social background of the patient, and the patient's wishes. Because budding was demonstrated to be an important risk factor for lymph node metastases in the project study by the JSCCR, additional intestinal resection has been added to the list of factors that should be considered in this revised edition. None of the guidelines in other countries include depth of invasion or budding as criteria for additional treatment.
CQ-2: Endoscopic resection of cM carcinomas and cSM carcinomas with a maximum diameter of 2 cm or greater Recommendation: Category B
• Accurate preoperative endoscopic diagnosis is essential, and whether resection by EMR, piecemeal EMR, or ESD is indicated is determined after taking the operator's skill in performing endoscopic resection into consideration. The lymph node metastasis rate of patients with a depth of invasion of 1,000 lm or above was 12.5% Side Memo 1
• Method for measuring depth of SM invasion ( Fig. 11 ):
-When it is possible to identify or estimate the location of the muscularis mucosae, depth of SM invasion is measured from the lower border of the muscularis mucosae of the lesion, regardless of the macroscopic type. -When it is not possible to identify or estimate the location of the muscularis mucosae, the depth of SM invasion is measured from the surface of the lesion. The phrase ''possible to identify or to estimate'' means that there is no ''deformity'' (i.e., disarray, dissection, rupture, fragmentation, etc.) of the muscularis mucosae as a result of SM invasion. If a deformed muscularis mucosa is used as the baseline of the measurement, the depth of SM invasion may be underestimated. Although judging whether there is a ''deformity'' is not always straightforward, if a desmoplastic reaction is present around the muscularis mucosae, it is assumed to be ''deformed.'' -For pedunculated lesions with a tangled muscularis mucosae, depth of SM invasion is measured as the distance between the point of deepest invasion and the reference line, which is defined as the boundary between the tumor head and the stalk (the boundary between the tumor area and the non-tumor area in the mucosa). Invasion by pedunculated lesions that is limited to within the head is defined as ''head invasion.''
• Method for assessing vascular invasion (Figs. 12, 13, 14):
-Attention to arteries is a key factor in assessing venous invasion. Venous invasion is highly likely when a circular, semicircular, or oblong cancer cell nest with regular margins is located in the vicinity of an artery and distant from the main lesion. If such a cancer cell nest is surrounded by venous wall structures (such as internal elastic membrane or perivascular smooth muscle), it can be concluded to represent venous invasion. However, the venous wall structures are often displaced or obliterated by the cancer cell nest, and it is difficult to recognize in hematoxylin and eosin stained sections. -The presence of cancer cells and cancer cell nests in the interstitial space suggests lymphatic invasion. A space filled with lymph and lymphocytes is especially likely to be a lymph vessel. When endothelial cells are identified around the space, the space can be concluded to represent a lymph vessel. However, it is often difficult to identify endothelial cells in specimens stained with hematoxylin and eosin, and spaces may be artifacts created during the process of preparing the specimen. -As stated above, evaluation of vascular invasion, which is an important indicator for determining treatment strategies for SM cancer, is often difficult in hematoxylin and eosin stained specimens. Special staining methods are useful for evaluating vascular invasion, such as elastica van Gieson staining or Victoria blue staining for venous invasion, and D2-40 immunostaining for lymphatic invasion.
• Method for assessing tumor budding ( Fig. 15 ):
[Definition of tumor budding] [79] A cancer cell nest consisting of 1 or less than 5 cells that infiltrates the interstitium at the invasive margin of the cancer.
[Grade of budding] After selecting one field where budding is the most intensive, the number of buddings is counted in a field measuring 0.785 mm 2 observed through a 209 objective lens (WHK 109 ocular lens). Depending on the number of buddings, the grade of budding is defined as follows: • Since laparoscopic surgery requires surgical skills that are different from those required for open abdominal surgery, and an understanding of regional anatomy is essential for laparoscopic surgery, the indication criteria should be determined depending on the skills of the surgical team.
Laparoscopic surgery is suitable for D2, D1 or D0 resection of colon and RS cancer, and is well indicated for the treatment of cStage 0 to cStage I disease. Because laparoscopic colectomy with D3 dissection is difficult, whether it is indicated for patients with cStage II to cStage III disease should be determined after carefully considering the skills of the surgical team. Laparoscopic surgery is also difficult in patients with transverse colon cancer, in severely obese patients, and in patients with severe adhesions. The efficacy and safety of laparoscopic surgery for rectal cancer has not been sufficiently established.
CQ-4: Resection of the primary tumor in patients with unresectable distant metastases Recommendation: Category B
• The initial resection of the primary tumor should be determined based on the performance status of each patient, such as the symptoms caused by the primary tumor, the status of distant metastases, and the patient's general condition. Resection of the primary tumor is often desirable when a patient has symptoms caused by the primary tumor that cannot be well controlled by other therapies, if the patient is sufficiently able to tolerate surgery, and the resection can be accomplished with acceptable morbidity.
CQ-5: Resection of peritoneal metastases (carcinomatous peritonitis)
Recommendation: Category C
• If patients with localized peritoneal dissemination (P1, P2) have no other unresectable distant metastases and resection will not result in excessive invasion, it is preferable to resect the disseminated tumors at the same time as the resection of the primary tumor.
CQ-6: Surgical treatment for local recurrence of rectal cancer
Recommendation: Category B
• Resection should be considered for local recurrence of rectal cancer when R0 resection is considered possible.
CQ-7: Resection in patients with liver and lung metastases
• The efficacy of resection in patients who have liver and lung metastases at the same time has been shown, and thus resection should be considered for patients with resectable liver and lung metastases.
However, there are insufficient data to determine the indication criteria for surgery. It is necessary to obtain informed consent after informing the patient of the rather low cure rate and the absence of outcome predictors.
CQ-8: Adjuvant chemotherapy after curative resection of liver metastases
• The efficacy of adjuvant chemotherapy after hepatectomy has not been established. It is desirable to investigate its efficacy in clinical trials.
CQ-9: Preoperative chemotherapy for resectable liver metastases
• The safety of preoperative chemotherapy for resectable liver metastases has not been established. It should be evaluated in properly designed clinical trials.
CQ-10: Chemotherapy for unresectable liver metastases
• Hepatectomy should be considered for liver metastases that have become resectable after successful chemotherapy.
No clear difference has been observed between hepatic arterial infusion therapy and systemic chemotherapy in terms of the prolongation of survival time of patients with unresectable liver metastases. • It is desirable to use bevacizumab as secondary treatment in patients who can be treated with bevacizumab and have not received it as primary treatment.
There is no clear evidence supporting the optimal dose in this situation (5 or 10 mg/kg) [44, 49] .
CQ-16: KRAS gene mutations and anti-EGFR antibody drugs
Recommendation: Category A
• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38-41, 47, 53, 55, 85-90] .
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• Anti-EGFR antibody drugs and EGFR immunostaining
Since most clinical research on cetuximab has been conducted on EGFR-positive patients, insurance coverage is limited to EGFR-positive patients. On the other hand, most clinical research on panitumumab has also been conducted on EGFR-positive patients, and evidence in regard to EGFR-negative patients is insufficient, but insurance coverage has been restricted to EGFR-positive patients. A recent report showed that there is no relationship between the effect of anti-EGFR antibody drugs and the level of EGFR expression assessed by immunostaining [91] .
• CPT-11 and UGT1A1 genetic polymorphism SN-38 is an active metabolite of CPT-11 and the UGT1A1 gene encodes an intrahepatic metabolizing enzyme which converts the active form SN-38 to the inactive form SN-38 G. In patients who are double heterozygotes for *6 and *28 or homozygotes for *6 or *28 of the UGT1A1 gene, the glucuronic acid conjugation capacity of UGT1A1 is known to be decreased and the metabolism of SN-38 to be delayed, and serious adverse drug reactions such as neutropenia may occur as a result. It is especially desirable to test for a UGT1A1 genetic polymorphism before administering CPT-11 to patients with a high serum bilirubin level, elderly patients, patients whose general condition is poor (e.g., PS2), and patients in whom severe toxicity (especially neutropenia) developed after the last administration of CPT-11. On the other hand, because CPT-11 toxicity cannot be predicted with certainty on the basis of the presence of a UGT1A1 genetic polymorphism alone, it is essential to monitor the patient's general condition during treatment and manage adverse drug reactions carefully regardless of whether a genetic polymorphism is detected.
CQ-17: Significance of preoperative chemoradiotherapy for rectal cancer
• Preoperative chemoradiotherapy is standard treatment for rectal cancer in Europe and the United States. However, there is insufficient evidence in support of its efficacy and safety in Japan, and it needs to be evaluated in properly designed clinical trials.
CQ-18: Chemoradiotherapy for unresectable locally advanced and locally recurrent rectal cancer
• The indication for chemoradiotherapy aiming at complete cure by R0 resection will also be considered for locally advanced or locally recurrent, unresectable rectal cancer.
CQ-19: Significance of surveillance after surgery of colorectal cancer 19A: Diagnosis of recurrence Recommendation: Category A
• Early detection of recurrence has been shown to contribute to an improvement in outcome, and postoperative surveillance examinations should be performed regularly. However, an optimal surveillance protocol incorporating the health economical point of view has not been sufficiently established.
19B: Multiple cancer Recommendation: Category B
• With the exception of hereditary colorectal cancer, a past medical history of colorectal cancer has not been demonstrated to be a risk factor for the development of cancer in other organs, and it is unnecessary to incorporate special surveillance for multiple cancer into the surveillance performed after curative surgery for colorectal cancer.
